for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Constellation Pharmaceuticals Inc

CNST.OQ

Latest Trade

8.71USD

Change

0.00(0.00%)

Volume

81,231

Today's Range

8.13

 - 

9.24

52 Week Range

4.01

 - 

14.04

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.71
Open
8.17
Volume
81,231
3M AVG Volume
1.46
Today's High
9.24
Today's Low
8.13
52 Week High
14.04
52 Week Low
4.01
Shares Out (MIL)
25.82
Market Cap (MIL)
224.92
Forward P/E
-2.82
Dividend (Yield %)
--

Next Event

Q3 2019 Constellation Pharmaceuticals Inc Earnings Release

Latest Developments

More

Constellation Pharmaceuticals Announces $65 Million Private Placement With New And Existing Investors

Constellation Pharmaceuticals Q2 Loss Per Share $0.80

Constellation Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is primarily if focused on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression and drug resistance. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-1205, and the other program is evaluating a compound, CPI-0610.

Industry

Biotechnology & Drugs

Contact Info

215 1st St Ste 200

+1.617.7140555

https://www.constellationpharma.com/

Executive Leadership

Mark A. Goldsmith

Independent Chairman of the Board

Jigar Raythatha

President, Chief Executive Officer, Director

Emma Reeve

Chief Financial Officer, Senior Vice President, Treasurer

Adrian Senderowicz

Senior Vice President, Chief Medical Officer

Patrick Trojer

Chief Scientific Officer

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-5.000

2019(E)

-3.087
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.35
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
29.13
LT Debt To Equity (MRQ)
29.13
Return on Investment (TTM)
-83.48
Return on Equity (TTM)
-72.84

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up